NLR-based nomogram predicts survival in hepatocellular carcinoma treated with TACE plus targeted immunotherapy.
A simple blood-based nomogram accurately predicts survival in advanced liver cancer treated with combination therapy, aiding treatment planning.
This retrospective cohort study developed and validated an NLR-based nomogram for predicting survival in unresectable HCC patients treated with TACE combined with targeted therapy and immune checkpoint inhibitors, showing NLR as a robust and accessible independent prognostic factor. The nomogram provides clinicians with a simple, blood-based tool to risk-stratify patients before complex combination treatment in a disease where accurate prognostication guides therapy decisions.
What the study was
- Study design
- Retrospective cohort study with nomogram development
- Population
- Unresectable HCC patients treated with TACE plus targeted immunotherapy
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- BMC cancer
Why it surfaced
Simple NLR-based nomogram for TACE+targeted immunotherapy survival prediction in HCC; NLR is routinely available, making this a potentially near-deployable prognostic tool if externally validated.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.